Multi-Component Ocular Composition for Dry Eye and Corneal UV Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye disease (DED) are often ineffective, time-consuming, expensive, or difficult to tolerate, and do not adequately address moderate to severe symptoms, while existing methods to protect the eye from UV damage lack direct delivery of antioxidants to the corneal surface.
Innovation Solution
A therapeutic composition comprising platelet-rich plasma (PRP), Acetylcysteine, Vitamin C, Vitamin B12, hyaluronic acid, and other antioxidants is administered to treat DED, promote eyelash growth, and protect the ocular surface from UV damage by delivering antioxidants directly to the cornea.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current DED treatments (artificial tears, antibiotics, corticosteroids) are used, then temporary symptom relief is achieved, but treatment effectiveness is insufficient for moderate to severe cases and treatment complexity increases
Solution Approach 1:
The patent combines multiple therapeutic agents (autologous serum, growth factors, antioxidants, anti-inflammatories) into a single composite eye drop formulation, replacing the need for multiple separate treatments and improving overall effectiveness while simplifying the treatment regimen
Solution Approach 2:
The invention uses composite material principles by formulating a multi-component pharmaceutical composition containing serum proteins, growth factors, antioxidants (vitamins C, E, A), and anti-inflammatory agents working synergistically to address multiple aspects of DED simultaneously
2Object-affected harmful factors
If oral antioxidant vitamins are taken to protect against UV damage, then systemic antioxidant protection is provided, but direct delivery to the corneal surface is insufficient since the cornea is avascular
Solution Approach 1:
The patent uses the tear film as an intermediary delivery system to transport antioxidants directly to the corneal surface, bypassing the avascular limitation and providing targeted protection where oral supplements cannot effectively reach
Solution Approach 2:
The invention replaces the systemic circulation route (oral administration through bloodstream) with a topical application route (eye drops through tear film), substituting the mechanical delivery system to achieve direct corneal surface protection
3Adaptability or versatility
If multiple separate treatments are administered for DED, then comprehensive symptom management is attempted, but treatment time increases and patient compliance becomes difficult
Solution Approach 1:
The single eye drop formulation performs multiple functions simultaneously: lubrication, antioxidant protection, anti-inflammatory action, and promotion of ocular surface healing, eliminating the need for multiple separate treatments and improving patient compliance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively alleviates DED symptoms, promotes eyelash growth, and provides ocular health benefits by stabilizing Vitamin C and delivering antioxidants to the cornea, reducing oxidative damage from UV exposure.
Implementation Method 1
The stabilizer may comprise ferulic acid
Data Source
AI summary
A composition for treating dry eye disease and/or promoting eyelash growth includes at least three compounds selected from the group consisting of platelet rich plasma (PRP), Acetylcysteine, Vitamin C (L-Ascorbic Acid), Vitamin B12, cyclosporine A, ferulic acid, Vitamin A, and hyaluronic acid (HA). A composition for maintaining and promoting ocular health, including, without limitation, Vitamin B12, Vitamin C, Vitamin D, and Vitamin E, Vitamin A, Acetylcysteine, hyaluronic acid, and ferulic acid. In a method for treatment of dry eye disease, for promoting eye lash growth, and for maintaining ocular health, the composition(s) is administered via an eye drop applicator or via a syringe or cannula to the eye of a patient.